Hims & Hers Health
HIMS
14.60
-1.42
-8.86%
Hims & Hers Health
US · HIMS
#1813 by market cap
Listed 1970
14.60
-1.42
-8.86%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.65, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +59.00% YoY
Margins
- Gross margin
- 73.84%
- Operating margin
- 4.50%
- Net margin
- 5.47%
Key ratios & quality
- Enterprise valuei
- 3.82B
- Altman Z-Scorei
- 2.65
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 82.56M | 148.76M | 271.88M | 526.92M | 872.00M | 1.48B | 2.35B |
| Gross profit | 44.61M | 109.45M | 204.49M | 408.72M | 714.95M | 1.17B | 1.73B |
| Selling & admin expenses | 119.02M | 113.36M | 249.56M | 370.78M | 576.32M | 846.61M | 1.19B |
| Research & development | -- | 11.24M | 22.38M | 29.24M | 48.23M | 78.82M | 149.30M |
| Operating profit | -74.41M | -15.14M | -115.04M | -68.70M | -29.45M | 61.90M | 105.61M |
| Pretax profit | -71.97M | -17.99M | -110.80M | -65.71M | -21.57M | 71.71M | 123.92M |
| Tax | 90.00K | 127.00K | -3.14M | -31.00K | 1.98M | -54.33M | -4.44M |
| Net profit | -72.06M | -18.11M | -107.66M | -65.68M | -23.55M | 126.04M | 128.37M |
| Basic EPS | -2 | -1 | -1 | 0 | 0 | 1 | 1 |
| Diluted EPS | -2.07 | -0.51 | -0.58 | -0.32 | -0.11 | 0.53 | 0.51 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 544.83M | 598.98M | 617.82M | 608.10M | 753.21M | 890.37M |
| Gross profit | 416.20M | 442.06M | 444.44M | 396.79M | 480.80M | 509.20M |
| Selling & admin expenses | 285.14M | 312.83M | 314.21M | 331.67M | 427.61M | 398.76M |
| Research & development | 37.85M | 40.58M | 40.96M | 46.94M | 54.90M | 69.39M |
| Operating profit | 26.72M | 11.81M | 9.19M | -78.32M | -97.19M | -66.15M |
| Pretax profit | 32.85M | 12.22M | 18.35M | -101.55M | -92.63M | -46.25M |
| Tax | -9.65M | -3.55M | -2.25M | -9.44M | -6.34M | -13.21M |
| Net profit | 42.51M | 15.77M | 20.60M | -92.12M | -86.29M | -33.04M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.17 | 0.06 | 0.08 | -0.40 | -0.37 | -0.14 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 69.61M | 113.08M | 269.91M | 216.60M | 265.05M | 395.83M | 767.64M |
| Cash & ST investments | 60.37M | 100.21M | 247.27M | 179.63M | 220.98M | 300.25M | 577.49M |
| Inventory | 4.22M | 3.54M | 13.56M | 21.56M | 22.46M | 64.43M | 80.13M |
| Total assets | 72.07M | 118.70M | 420.59M | 366.34M | 441.19M | 707.54M | 2.15B |
| Total current liabilities | 20.62M | 15.23M | 79.22M | 47.94M | 88.47M | 221.37M | 404.43M |
| Short-term debt | 1.52M | -- | 1.37M | 1.66M | 1.28M | 1.89M | 4.84M |
| Long-term debt | -- | -- | -- | -- | -- | -- | 972.58M |
| Total liabilities | 207,363,000.00 | 265,571,000.00 | 85,966,000.00 | 54,600,000.00 | 97,157,000.00 | 230,823,000.00 | 1,613,777,000.00 |
| Total equity | -135.29M | -146.87M | 334.62M | 311.74M | 344.03M | 476.72M | 540.93M |
| Retained earnings | -153.18M | -171.29M | -278.95M | -344.63M | -368.18M | -242.14M | -113.77M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 1.36B | 845.26M | 767.64M | 1.05B | 1.38B | 1.32B |
| Cash & ST investments | 1.14B | 629.74M | 577.49M | 750.88M | 841.05M | 712.22M |
| Inventory | 141.80M | 105.99M | 80.13M | 79.07M | 87.78M | 107.85M |
| Total assets | 1.88B | 2.23B | 2.15B | 2.27B | 3.63B | 3.55B |
| Total current liabilities | 272.23M | 450.79M | 404.43M | 618.78M | 1.48B | 1.44B |
| Short-term debt | 3.14M | 3.42M | 4.84M | 5.58M | 11.55M | 10.85M |
| Long-term debt | 969.47M | 971.02M | 972.58M | 974.11M | 1.37B | 1.37B |
| Total liabilities | 1,314,886,000.00 | 1,652,322,000.00 | 1,613,777,000.00 | 1,820,876,000.00 | 3,304,742,000.00 | 3,191,565,000.00 |
| Total equity | 562.70M | 580.98M | 540.93M | 446.17M | 324.07M | 355.30M |
| Retained earnings | -150.15M | -134.37M | -113.77M | -205.89M | -292.18M | -325.22M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -74.87M | -2.48M | -34.41M | -26.53M | 73.48M | 251.08M | 300.01M |
| Depreciation & amortization | 260.00K | 1.06M | 4.08M | 7.47M | 9.52M | 17.09M | 54.50M |
| Free cash flow | -76.65M | -6.71M | -39.42M | -33.78M | 46.99M | 198.33M | 57.42M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 250.66M | 0 | -2.00M | -83.04M | -89.96M |
| Ending cash balance | 22.80M | 28.35M | 72.64M | 47.63M | 97.52M | 221.44M | 228.62M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -19.12M | 148.72M | 61.31M | 89.36M | -35.94M | 65.39M |
| Depreciation & amortization | 10.47M | 17.67M | 18.09M | 21.95M | 29.48M | 38.21M |
| Free cash flow | -69.43M | 79.36M | -2.57M | 53.03M | -68.19M | 25.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -80.48M | -- | -- | -- |
| Ending cash balance | 1.12B | 345.78M | 228.62M | 222.27M | 609.81M | 605.60M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -114.69 | -20.32 | -7.18 | 30.71 | 25.23 |
| ROA %i | -99.99 | -18.99 | -39.93 | -16.69 | -5.83 | 21.94 | 8.97 |
| ROIC %i | -- | -- | -110.65 | -19.99 | -7.02 | 29.94 | 11.94 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -17.25 |
| EBIT margin %i | -86.73 | -10.18 | -40.75 | -13.04 | -3.38 | 4.19 | 4.50 |
| FCF / sales %i | -- | -- | -- | -- | 5.39 | 13.43 | 2.45 |
| Current ratioi | 3.38 | 7.43 | 3.41 | 4.52 | 3.00 | 1.79 | 1.90 |
| Quick ratioi | 2.97 | 6.63 | 3.17 | 3.81 | 2.57 | 1.38 | 1.51 |
| Debt / assetsi | 2.10 | 0.00 | 1.30 | 1.45 | 2.25 | 1.60 | 52.01 |
| LT debt / equityi | -- | -- | 1.23 | 1.17 | 2.52 | 1.98 | 206.27 |
| Interest coveragei | -194.05 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 85.49 | 80.31 | 75.77 | 64.55 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 41.88 | 26.21 | 25.23 | -2.66 | -32.03 | -40.77 |
| ROA %i | 16.42 | 9.44 | 8.97 | -0.84 | -5.16 | -6.60 |
| ROIC %i | 19.55 | 12.44 | 11.94 | -1.21 | -8.17 | -10.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.24 | 5.20 | 4.50 | -1.29 | -5.99 | -8.10 |
| FCF / sales %i | 5.94 | 5.40 | 2.45 | 2.55 | 2.39 | 0.29 |
| Current ratioi | 4.98 | 1.88 | 1.90 | 1.69 | 0.93 | 0.92 |
| Quick ratioi | 4.23 | 1.49 | 1.51 | 1.46 | 0.82 | 0.79 |
| Debt / assetsi | 55.62 | 50.06 | 52.01 | 49.93 | 42.61 | 44.00 |
| LT debt / equityi | 185.05 | 191.85 | 206.27 | 252.47 | 473.56 | 436.23 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Hims & Hers Health discussion 0 comments